Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 18/20 | 0.65 |
| ▸ | THRB | P10828 | 18/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044639 | 0.91 | THRA (0.65) | THRATHRB | |
| SCHEMBL13381638 | 0.80 | THRA (0.50) | THRATHRBGAA | |
| SCHEMBL282073 | 0.79 | THRB (1.00) | THRATHRB | |
| SCHEMBL4347907 | 0.73 | THRA (0.71) | THRATHRB | |
| SCHEMBL13867768 | 0.70 | THRA (0.58) | THRATHRB | |
| SCHEMBL283081 | 0.70 | THRA (1.00) | THRATHRB | |
| SCHEMBL13044659 | 0.70 | THRB (0.83) | THRATHRB | |
| SCHEMBL282132 | 0.69 | THRB (0.66) | THRATHRB | |
| Mb07344 SCHEMBL29378732 | 0.69 | THRB (1.00) | THRATHRB | |
| Mb07344 SCHEMBL282003 | 0.69 | THRB (1.00) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | TSHR, TPO, THRA | THRA 3/4885THRB 4/4885RORC 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.